IQ-AI, Ltd.

IQ-AI, Ltd.

  • News & Announcements
  • Shareholder Information
  • Investor Relations
  • Significant Shareholders
  • Publications
  • Home
  • Corporate News & Announcements
  • IQ-AI News & Announcements
  • Placing
 

BLOG

IQ-AI
Thursday, 07 October 2021 / Published in IQ-AI News & Announcements

Placing

/**/
RNS Number : 3746O
IQ-AI Limited
07 October 2021
 

7 October 2021

IQ-AI Ltd

(“IQ-AI” or the “Company”)

 

Placing

 

IQ-AI is pleased to announce that it has raised £620,000 through the placing of 12,400,000 new ordinary shares of 0.01p each in the Company (“Ordinary Shares”, the “Placing Shares”) at a price of 5 pence per Placing Share (the “Placing Price”, the “Placing”) through Peterhouse Capital Limited, the Company’s Financial Adviser and Broker.

 

Trevor Brown, CEO of IQ-AI, has subscribed £150,000 for 3,000,000 Placing Shares in the Placing. Following completion of the Placing, Trevor Brown will be interested in 52,813,236 Ordinary Shares, representing approximately 28.94 per cent of the Company’s enlarged issued ordinary share capital.

 

Subscribers in the Placing have been issued with warrants to subscribe for a further 12,400,000 Ordinary Shares at a price of 7.5p per share, exercisable for 3 months.

 

The net proceeds of the Placing will be invested in the continuing development of the Company’s Software Platforms, IB Zero G, IB Trax and IB CAD, and for general working capital purposes.

 

Application will be made for the Placing Shares to be admitted to the Standard List segment of the Official List and to trading on the main market of the London Stock Exchange (“Admission”). It is expected that Admission will become effective and that dealings in the Placing Shares will commence at 8.00am on or around 14 October 2021.

 

Following completion of the Placing, the Company’s issued share capital will consist of 182,507,609 Ordinary Shares. This figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA’s Disclosure and Transparency Rules.

The Directors of the Company accept responsibility for the contents of this announcement.

 

-ENDS-

 

For further information, please contact:

IQ-AI Limited

Trevor Brown/Brett Skelly/Vinod Kaushal

Tel: 020 7469 0930

 

Peterhouse Capital Limited (Financial Adviser and Broker)

Lucy Williams/Heena Karani

Tel: 020 7220 9797

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
Article source
  • Tweet

What you can read next

IQ-AI sponsors Phase 1 GBM treatment trial
IMAGING BIOMETRICS AND MCW AWARDED NIH/NCI GRANT
IQ-AI 2020 Annual General Meeting Notice

Recent Posts

  • IQ-AI shares cease trading on the OTCQB

    /**/ RNS Number : 9599M IQ-AI Limited 19 Septem...
  • Reduced Gadolinium Approach Validated’

    /**/ RNS Number : 7871L IQ-AI Limited 08 Septem...
  • Update on Collaboration Agreement with Mayo Clinic

    /**/ RNS Number : 8096J IQ-AI Limited 18 August...
  • IB & GE HealthCare Enter into Commercial Agreement

    /**/ RNS Number : 8077J IQ-AI Limited 18 August...
  • Half-year Report

    /**/ RNS Number : 5460J IQ-AI Limited 17 August...
  • Policies
  • Investor Information

iq-ai@imagingbiometrics.com

P. O. Box 264
Forum 4, Grenville Street
St Helier, Jersey, Channel Islands
JE4 8TQ

Copyright © 2015-2023 IQ-AI. All Rights Reserved
TOP
Our website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish.AcceptReject Read More
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT